Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers.

Kim MS, Kim JS, Cho W, Park HJ, Hwang SJ.

Int J Biol Macromol. 2013 Aug;59:138-42. doi: 10.1016/j.ijbiomac.2013.03.068. Epub 2013 Apr 6.

PMID:
23567288
2.

Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.

Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ.

Eur J Pharm Biopharm. 2008 Jun;69(2):454-65. doi: 10.1016/j.ejpb.2008.01.007. Epub 2008 Jan 18.

PMID:
18359211
3.

The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller JM.

AAPS J. 2013 Apr;15(2):347-53. doi: 10.1208/s12248-012-9445-3. Epub 2012 Dec 15.

4.
5.

Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique.

Ha ES, Baek IH, Cho W, Hwang SJ, Kim MS.

Chem Pharm Bull (Tokyo). 2014;62(6):545-51.

7.

Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.

Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M.

Pharm Res. 2012 Oct;29(10):2765-76.

PMID:
22315020
8.

Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64.

Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M, Van den Mooter G.

Eur J Pharm Sci. 2005 Jun;25(2-3):313-20.

PMID:
15911228
9.

Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.

Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ.

Int J Nanomedicine. 2011;6:2997-3009. doi: 10.2147/IJN.S26546. Epub 2011 Nov 24.

10.

Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.

Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ.

Int J Pharm. 2008 Jul 9;359(1-2):211-9. doi: 10.1016/j.ijpharm.2008.04.006. Epub 2008 Apr 12.

PMID:
18501538
11.

Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.

Ha ES, Kim JS, Baek IH, Yoo JW, Jung Y, Moon HR, Kim MS.

Drug Des Devel Ther. 2015 Aug 4;9:4269-77. doi: 10.2147/DDDT.S90706. eCollection 2015.

12.

Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion.

Zheng X, Yang R, Zhang Y, Wang Z, Tang X, Zheng L.

Drug Dev Ind Pharm. 2007 Jul;33(7):783-9.

PMID:
17654027
13.

Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs.

Kim MS.

Artif Cells Nanomed Biotechnol. 2013 Dec;41(6):363-7. doi: 10.3109/21691401.2012.762369. Epub 2013 Jan 22.

PMID:
23336707
14.

Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation.

Khan FN, Dehghan MH.

AAPS PharmSciTech. 2011 Dec;12(4):1077-86. doi: 10.1208/s12249-011-9673-3. Epub 2011 Aug 31.

15.

Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.

Konno H, Handa T, Alonzo DE, Taylor LS.

Eur J Pharm Biopharm. 2008 Oct;70(2):493-9. doi: 10.1016/j.ejpb.2008.05.023. Epub 2008 Jun 6.

PMID:
18577451
16.

Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5.

Janssens S, de Armas HN, Roberts CJ, Van den Mooter G.

J Pharm Sci. 2008 Jun;97(6):2110-20.

PMID:
17847067
17.

Part I: characterization of solid dispersions of nimodipine prepared by hot-melt extrusion.

Zheng X, Yang R, Tang X, Zheng L.

Drug Dev Ind Pharm. 2007 Jul;33(7):791-802. Erratum in: Drug Dev Ind Pharm. 2008 Feb;34(2):232-3.

PMID:
17654028
18.

Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364.

Sotthivirat S, McKelvey C, Moser J, Rege B, Xu W, Zhang D.

Int J Pharm. 2013 Aug 16;452(1-2):73-81. doi: 10.1016/j.ijpharm.2013.04.037. Epub 2013 May 4.

PMID:
23651642
19.

Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process.

Park J, Cho W, Cha KH, Ahn J, Han K, Hwang SJ.

Int J Pharm. 2013 Jan 30;441(1-2):50-5. doi: 10.1016/j.ijpharm.2012.12.020. Epub 2012 Dec 20.

PMID:
23262425
20.

Dissolution and precipitation behavior of amorphous solid dispersions.

Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GG, Taylor LS.

J Pharm Sci. 2011 Aug;100(8):3316-31. doi: 10.1002/jps.22579. Epub 2011 May 23.

PMID:
21607951
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk